Usana Health Sciences Inc: Form 10-Q for the period ended Mar 29, 2025
Filed with the SEC on May 6, 2025 and accepted by EDGAR at May 6, 2025, 14:42 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-29. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-12-29 to 2025-03-29 | $249.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-12-29 to 2025-03-29 | $52.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-12-29 to 2025-03-29 | $197.1m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-12-29 to 2025-03-29 | $91.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-12-29 to 2025-03-29 | $15.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-12-29 to 2025-03-29 | $411.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-12-29 to 2025-03-29 | $7.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-12-29 to 2025-03-29 | $9.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-12-29 to 2025-03-29 | $0.49 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-12-29 to 2025-03-29 | $0.49 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-12-29 to 2025-03-29 | 19,085,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-12-29 to 2025-03-29 | $15.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-12-29 to 2025-03-29 | $2.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2024-12-29 to 2025-03-29 | $12.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-03-29 | $179.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-29 | $281.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-29 | $746.6m | us-gaap:Assets |
| Current liabilities | At period end2025-03-29 | $137.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-29 | $162.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-03-29 | $529.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000896264-25-000126. Last ingested by Listed: Nov 3, 2026, 19:18 ET. Listed shows no prices and gives no investment advice.